You are here: Home » Reuters » News
Business Standard

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

Reuters  |  COPENHAGEN/BRUSSELS 

By Jacob Gronholt-Pedersen and Robert-Jan BartunekCOPENHAGEN/BRUSSELS (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.Ablynx rejected Novo's latest takeover approach and analysts predict the Danish group, whose new chief executive is trying to expand by buying drugs developed by competitors, might face counterbidders and would need to raise its bid.Shares in Ablynx closed up 45 percent at ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, January 08 2018. 23:30 IST
RECOMMENDED FOR YOU